Open AccessIbritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma
Author(s) -
Desai Sanjal,
Moustafa Muhamad Alhaj,
Wiseman Gregory,
Witzig Thomas
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13895
Subject(s) - radioimmunotherapy , ibritumomab tiuxetan , medicine , follicular lymphoma , lymphoma , gastrointestinal tract , follicular phase , cd20 , radiation therapy , rituximab , oncology , nuclear medicine , monoclonal antibody , antibody , immunology
Abstract Primary gastrointestinal follicular lymphoma (PGIFL) is characterized by localized involvement of the gastrointestinal (GI) tract. PGIFL usually runs an indolent course. External beam radiation therapy is curative in a substantial proportion of localized follicular lymphomas, but GI toxicities may discourage its use in PGIFL. Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti‐CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope. RIT delivers confined high‐intensity radiation with short path length specifically targeting lymphoma cells and sparing normal tissue. In this case series report, we included six cases of PGIFL treated with RIT. All patients had low‐risk, localized, and nonbulky disease. All patients responded completely and were relapse‐free for the duration of follow‐up. Hematologic toxicities were seen, but none were serious. RIT is a potentially curative treatment option in PGIFL with a tolerable toxicity profile.